These and other GLP1-RA diabetes/weight-loss meds can also boost outcomes for folks battling chronic kidney disease, new ...

Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been approved by the US Food and Drug Administration to reduce certain risks associated with ...

GLP-1 medications are renowned for their ability to treat type 2 diabetes and aid weight loss. Now, there's a new benefit to ...

Ozempic becomes the first GLP-1 treatment option for people with type 2 diabetes and chronic kidney disease Mario Tama ... was made following a clinical trial of more than 3,500 people where ...

which reported in March 2024 that—in a trial of more than 3,500 people with type 2 diabetes—Ozempic lowered the risk of kidney disease progression and death from kidney or cardiovascular ...

Semaglutide reduced the risk of kidney disease worsening, renal failure, and CV death by 24% compared with placebo. The approval was based on data from the randomized, double-blind, placebo-controlled ...

Ozempic's expanded approval in the U.S. could transform how doctors treat patients with the condition, which involves a gradual loss of kidney function.

For years, people taking Ozempic or other drugs in the same class for diabetes and weight loss have noticed the medicines don ...

The US Food and Drug Administration (FDA) approved semaglutide (Ozempic ... FLOW kidney outcomes trial, which involved more than 3500 individuals with chronic kidney disease and type 2 diabetes ...